The team is led by partner Dominik Hohler (Corporate / M&A - pictured) and managing associate Fabienne Limacher (Tax) and also includes managing associate Boris Räber (Corporate / M&A) and Judith Rothen (Corporate / M&
Tags :Walder Wyss
The team has been led by partner Urs P. Gnos (Corporate/M&A - pictured) and further included managing associate Fabienne Anner (Corporate/M&A), partner Lukas Wyss (Finance), partner Maurus Winzap (Tax) and trainee
The team was led by partner Alexander Gutmans (Transaction/M&A & Venture Capital - pictured) and partner Robert von Rosen (Transaction/M&A & Venture Capital)
Walder Wyss’ IP team successfully represented the pharmaceutical company Merck in appeal proceedings before the Swiss Federal Supreme Court against its US competitor MSD. The case Following World War I, Merck’s US subsidiary, which
The team was led by partner Florian Gunz Niedermann (Corporate/ M&A - pictured) and also included associate Sebastian Wyler (Corporate / M&A).
Walder Wyss acted as Swiss counsel to CRISPR in connection with the transaction. The team was led by partner Alex Nikitine. Homburger acted as legal counsel to Goldman Sachs & Co. LLC, BofA Securities, Inc. and
Walder Wyss advised Crédit Mutuel Equity in relation to this investment. The team was led by partner Luc Defferrard (M&A)
Walder Wyss advised Pexapark in this transaction. The team included partners Ramona Wyss (Energy/M&A), Florian Gunz (M&A) and associate Timon Nydegger (M&A).
After receipt of the required regulatory permits and completion of the agreed carve-out the transaction was closed on 8 June 2020. Walder Wyss acted as lead counsel to the private sellers
Filtration Group (Chicago), an affiliate of Madison Industries, acquired Switzerland based Oxyphen, an innovator in track-etched membranes.
